Irreversible Pulpitis. Diseases of pulp and periapical tissues
Conditions
Interventions
Intervention 1: Intervention group: 1.2 ml lidocain2% in combination with epinephrine 1/100000 (produced by DarouPakhsh Company) in addition to 0.6 ml Magnesium Sulphate 50%( produced by Pasteur Insti
Treatment - Drugs
Intervention group: 1.2 ml lidocain2% in combination with epinephrine 1/100000 (produced by DarouPakhsh Company) in addition to 0.6 ml Magnesium Sulphate 50%( produced by Pasteur Institute) will be pr
Control group: 1.2 ml Lidocaine2% in combination with Epinephrine1/100000 (produced by DarouPakhsh Company) in addition to 0.6 ml Normal Salin will be prescribed in single dosage.
Sponsors
Vice Chancellor of research of Dental branch, Tehran Islamic Azad University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with symptomatic irreversible pulpitis referred to endodontics Islamic Azad University in Tehran; willingness to participate in the study. Exclusion criteria: any systemic diseases, pregnancy and lactation, narcotic using; cigarette smoking, analgesic drug usage during 24 hours before treatment, allergy to anesthetic drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: During Access Cavity creation, During Exposure,Initial initial instrumentation. Method of measurement: Visual Analogue Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Unset of anesthesia. Timepoint: 3-6-9 minute after Intervention. Method of measurement: Electric pulp tester. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Amirabbas Moshari
Department of Endodontics, School of Dentistry, Islamic Azad University
Outcome results
None listed